Intelligence Platform
Patents
Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 10364258
Heteroaryl inhibitors of PDE4
granted patentUS 10364238
N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
granted patentUS 10363261
Enolase inhibitors and methods of treatment therewith
granted patentUS 10358421
Piperidine derivatives as HDAC1/2 inhibitors
granted patentUS 10351532
Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
granted patentUS 10344033
2-aminoquinazoline derivatives as P70S6 kinase inhibitors
granted patentUS 10344025
GLS1 inhibitors for treating disease
granted patentUS 10342786
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted patentUS 10337005
Oligonucleotide-based inhibitors comprising locked nucleic acid motif
granted patentUS 10336773
Neprilysin inhibitors
granted patentUS 10335404
Methods of treating cancer patients with farnesyltransferase inhibitors
granted patentUS 10335382
Use of hydrogen sulfide synthesis inhibitors for cancer therapy
granted patentUS 10329298
Inhibitors of cellular metabolic processes
granted patentUS 10329283
G protein-coupled receptor kinase inhibitors and methods for use of the same
granted patentUS 10329260
Human plasma kallikrein inhibitors
granted patentUS 10316371
Screening methods for identifying specific Staphylococcus aureus inhibitors
granted patentUS 10316038
Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
granted patentUS 10315984
Neprilysin inhibitors
granted patentUS 10314908
Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to
granted patentUS 10308656
Small molecule inhibitors of Ku70/80 and uses thereof
granted patentUS 10308608
Histone deacetylase inhibitors
granted patentUS 10308605
Proton pump inhibitors
granted patentUS 10307423
FBXO3 inhibitors
granted patentUS 10307407
9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
granted